1. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.36
Figure 2 Human induced pluripotent stem cell (hiPSC)-based platforms for drug development
Figure 2 | Human induced pluripotent stem cell (hiPSC)-based platforms for drug development. Various cell types can be derived from patients' somatic cells using different techniques in multiple steps: somatic cell isolation, hiPSC reprogramming, and hiPSC differentiation. The resultant hiPSC-derived cells can be subjected to comprehensive drug testing, including assessment of contractility, arrhythmia potential, metabolism, cell morphology, and synthetic function. Co-MIP, codon-optimized mini-intronic plasmid; eNOS, endothelial nitric oxide synthase; GF, growth factors; iPSC, induced pluripotent stem cell; NO, nitric oxide; PBMC, peripheral blood mononuclear cell; SM, small molecules.
Chen, I. Y. et al. (2016) Induced pluripotent stem cells: at the heart of cardiovascular precision medicine
Nat. Rev. Cardiol. doi: /nrcardio